International Journal of Medical Science and Clinical Research Studies

ISSN(print): 2767-8326, ISSN(online): 2767-8342

Volume 04 Issue 08 August 2024

Page No: 1514-1516

DOI: https://doi.org/10.47191/ijmscrs/v4-i08-15, Impact Factor: 7.949

Adverse Associated with the Cosmetic Usage of Botulinum Toxin

Pablo Alberto Mendoza Sanchez[1], Francisco Alberto Montaño Vasquez[2], Jose Manuel Gómez Pérez[3], Diego Clemente Moreno[2], Jesús Alberto Lizárraga Castro[3], Fernando Rodríguez Morales[4], Erik Beltrán Serrano[5], Román Esteban Hernández González[6], Angel Humberto Picón Piñon[2], Marisela Silva Garcia[1], Alondra Yesenia Ramírez Gómez[1]

[1]Hospital General Dr Miguel Silva

[2]Hospital General Regional IMSS II

[3]Hospital Regional De Alta Especialidad Gustavo A Rovirosa Pérez.

[4]Hospital General Regional No.1 Charo

[5]Hospital: Hospital Regional ISSSTE León, Guanajuato.

[6]IMSS Tlaxcala Hgz1 La Loma

ABSTRACT

Botulinum toxin, the primary cause of botulism, is used in therapeutic environments for several objectives. Botulinum toxin injections effectively treat cosmetic concerns caused or exacerbated by muscular contractions by regulating local neurotransmission. The effects of therapy are temporary; noticeable muscular recovery often occurs many months after treatment, as shown in clinical settings. Improper placement of injections or the spread of toxins to undesired areas may lead to significant muscle weakness, perhaps causing temporary deformity or functional issues. Therapeutic techniques may be used to fix visual problems including eyelid ptosis and a puzzling brow. Under different conditions, advancement relies on the gradual decrease in the effectiveness of the botulinum toxin.

Introduction

Botulinum toxin is a neurotoxin derived from the bacterium Clostridium botulinum, which is responsible for causing botulism. It is administered by injections and acts as a neuromodulator. Botulinum toxin hampers or immobilizes skeletal muscle by obstructing the transfer of signals between nerve endings and muscle fibers. Originally used for medicinal applications, the administration of botulinum toxin by injection has since gained significant popularity as a prominent method for facial rejuvenation.

ARTICLE DETAILS

Published On:
16 August 2024

Available on:
https://ijmscr.org/



Figure 1

Botulinum toxin injection is a very safe procedure for treating cosmetic imperfections induced or worsened by muscular contractions, such as noticeable glabellar wrinkles. Botulinum toxin has a brief duration of effect, with muscle function often returning to normal within a few months.

Adverse Reactions and Adverse Events

Botulinum toxin used for cosmetic purposes is considered safe when patients undergo thorough screening and get the appropriate dosage and injection technique. The predominant adverse effects are moderate and temporary edema or contusion at the site of injection, minor cephalalgia, or symptoms resembling influenza. Muscle function impairment may also occur, however this is often a result of inadequate injection technique or inappropriate patient selection. It is advisable to use a cautious treatment strategy since lesser dosages are less prone to inducing unwanted side effects.

Botulinum toxin diffusion may sometimes result in effects on nearby muscles or glands that are next to the intended muscles being treated. Dissemination of toxins in the upper face may result in enduring and distressing consequences lasting from 2 to 12 weeks, including brow ptosis (excessive weakening of the frontalis muscle) and eyelid ptosis. In addition, a confused or asymmetrical look, sometimes referred to as a "Mr. Spock" brow, may occur due to selective weakening of the medial frontalis muscles. This allows the unaffected lateral frontalis muscle fibers to raise the outer part of the brow. In the upper face, some other adverse effects that may occur include diplopia (double vision), ectropion (outward turning of the eyelid), lower eyelid droop, epiphora (excessive crying), reduced strength of eye closure, and dry eye.



Figure 2. Ptosis due botox administration

Therapeutic complications in the lower face often include effects on muscle function and facial expression. The primary cause of these adverse effects is the overuse or improper administration of the substance. When injections are administered in close proximity to the mouth, namely in the mental fold or when botulinum toxin affects the orbicularis oris muscle, it is more probable to have flaccid cheek, incompetent mouth, asymmetrical grin, and the inability to whistle. Administering high doses in the neck area may result in dysphagia and weakening of the neck flexor muscles.

Administering Praclonidine drops two to three times daily until the condition resolves will effectively alleviate eyelid ptosis. This often leads to a little elevation of the eyelids, often measuring 1 to 2 millimeters. To address the puzzling brow, one might inject the lateral frontalis musculature. Additional functional side effects that are not responsive to compensatory treatment subside after the effects of the botulinum toxin diminish.

An analysis of the botulinum toxin data reveals an outstanding safety record. The notable adverse effects reported were reactions at the site of injection, headache, localized facial paralysis, muscle weakness, flu-like symptoms, difficulty swallowing, compromised breathing, irregular heart rhythm, seizure, changes in vision, and allergic reactions.

While the likelihood of experiencing significant negative effects is low while using cosmetics, there have been reported cases of aspiration, dysphagia, pneumonia, allergy, botulism, and even death associated with the use of botulinum toxin.

Due to the temporary nature of botulinum toxin, patients will need further treatment to sustain their improvement. An examination of more than 4000 treatments in 945 persons who had botulinum toxin therapy for upper facial wrinkles was conducted to assess the safety of repeated treatments. Patients must have undergone a minimum of three consecutive treatment cycles. Only adverse effects ranging from moderate to severe were found, with bruising and ptosis being the most common. In addition, the frequency of negative side effects decreased with repeated injections, a result that has been reported in studies on the therapeutic use of botulinum toxin type A. Repeated administrations of abobotulinumtoxinA in large open label trials were also shown to be well tolerated.

The onabotulinumtoxin A, abobotulinumtoxin A, and prabotulinumtoxin A preparations that are available for purchase are combined with clostridial proteins, which might potentially impact their ability to provoke an immune response. While there have been some studies linking the formation of antibodies against botulinum toxin to reduced treatment efficacy, this occurrence seems to be rare, especially in patients receiving therapy for cosmetic purposes. Out of a total of 2240 patients who received onabotulinumtoxinA for various reasons (including 718 patients treated for glabellar lines), only 11 individuals showed seroconversion. This information was obtained from a meta-analysis of randomized trials and open label studies conducted between 1999 and 2007. Out of all the people who became seropositive, just three of them did not respond to therapy. It is important to note that none of these individuals had treatment only for cosmetic purposes.

CONCLUSION

Administering the minimal efficacious dosages at the maximum feasible intervals between injections might potentially decrease the likelihood of an immune response. Due to the absence of complexing proteins, the immunogenicity of incobotulinumtoxin A may vary from that of previously existing complexed products.

REFERENCES

I. Nicoletti, M. M., Anatriello, A., Liguori, V., Cantone, A., di Mauro, G., Izzo, I., ... & Scavone, C. (2023). Skin toxicities associated with botulin toxin injection for aesthetic procedures: data from the European spontaneous reporting system. Pharmaceuticals, 16(11), 1611.

II. de Oliveira, A. C. C., Leite, S. S., Brito, F. D. Q., da Silva, A. R. M., Amorim, M. T., Carneiro, A. M. F., ... & Arruda, J. E. G. (2024). Adverse events related to botulinum toxin type A, reported in Brazil between 2019 and 2022. Caderno Pedagógico, 21(7), e5823-e5823.

III. Samizadeh, S., & De Boulle, K. (2023). Complications of toxins and fillers in facial aesthetics. Primary Dental Journal, 12(3), 65-72.

IV. Michon, A. (2023). Botulinum toxin for cosmetic treatments in young adults: An evidence-based review and survey on current practice among aesthetic practitioners. Journal of Cosmetic Dermatology, 22(1), 128-139.

V. Glaser, K., & Glaser, D. A. (2023). Cosmetic Uses of Botulinum Neurotoxins for the Upper Face. Manual of Botulinum Toxin Therapy, 188.

VI. Li, Y., Zheng, Q., Lin, J., Su, X., Zhuang, J., Wei, Q., & Hu, J. (2024). Mild Allergic Reactions after Botulinum Toxin Injection: A Case Series and Literature Review. Plastic and Reconstructive Surgery–Global Open, 12(5), e5845.

VII. Lipham, W. J., & Melicher, J. S. (2024). What Is Botulinum Toxin and How Does It Work?. In Cosmetic and clinical applications of Botox and dermal fillers (pp. 5-10). CRC Press.

VIII. Richardson, J., & Viviano, S. (2024). From Beauty to Botulism: A Case Report Highlighting the Rare Risk of Botox Administration. Cureus, 16(2).

IX. Karcioglu, O., Akman, C., & Atnis, I. (2024). Efficacy and Safety Analysis of Botox Application and Iatrogenic Botulism: Panacea or Peril?. Current Pharmaceutical Design, 30(8), 578-588.

X. Mukherjee, J., Naresh, V., Krishna, A., Boggula, N., & Rao, T. R. (2023). Botox Treatment: A Comprehensive Review. Asian Journal of Medicine and Health, 21(11), 349-358.

XI. Haney, B. (2024). Neurotoxin Adverse Reactions. In Aesthetic Procedures: Nurse Practitioner's Guide to Cosmetic Dermatology (pp. 149-157). Cham: Springer International Publishing.